Citius Pharmaceuticals, Inc. (CTXR) reported topline results from the phase 3 trial of I/ONTAK for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. The company said the topline results for I/ONTAK were consistent with the prior formulation. No new safety signals were identified.
"The topline results demonstrated anti-tumor activity in the treatment of persistent or recurrent CTCL, an incurable disease. Based on the topline data, I/ONTAK provided disease control without cumulative toxicity. The topline data further demonstrate that I/ONTAK has an average time to response within one to two cycles of treatment in patients that have failed multiple prior therapies," said Myron Czuczman, Chief Medical Officer of Citius.
Based on the data, Citius expects filing a biologics license application with the FDA in the second half of 2022.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.